Antithrombotic Drugs Market By Drug Type (Anticoagulant Drug, Antiplatelet Drug, Thrombolytic Drug); By Route of Administration, By Application, By End User, and Geography - Trend, Analysis, and Forecast, 2023-2032

Antithrombotic Drugs Market By Drug Type (Anticoagulant Drug, Antiplatelet Drug, Thrombolytic Drug); By Route of Administration, By Application, By End User, and Geography - Trend, Analysis, and Forecast, 2023-2032

The antithrombotic drugs market size is predicted treach USD 105.33 billion by 2032, in accordance with a new study by Polaris Market Research. The report Antithrombotic Drugs Market By Drug Type (Anticoagulant Drug, Antiplatelet Drug, Thrombolytic Drug); By Route of Administration, By Application, By End User, and Geography - Trend, Analysis, and Forecast, 2023-2032” gives a complete foresight intcurrent market dynamics and contribute analysis on future market growth.

Rising cardiovascular disease incidence is anticipated tfuel market expansion over the forecast period. Some of the key factors propelling the growth of the worldwide antiplatelet medicines market are the rising prevalence of cardiovascular illnesses, an aging population, and a sedentary lifestyle. In both developed and developing economies, cardiovascular illnesses constitute the main cause of death.

For instance, according tdata from the American Heart Association, at least 3 t6 million persons in the United States alone had atrial fibrillation in June 2018, and the figure is expected trise t6 t16 million by the year 2050. 3,658 heart transplants were carried out in the United States in 2020. The states of California (496), Texas (302), Florida (288), and New York performed the most heart transplants (250).

The antiplatelet market is influenced by things including the widespread use of antithrombotic/anticoagulant medications, an increase in thrombotic occurrences, an aging population, and recent pharmaceutical advancements.

The market for antithrombotic/anticoagulant medications is anticipated texpand rapidly throughout the forecast period due tfactors including the increased availability of these medications and the prevalence of chronic thrombotic diseases that necessitate long-term medication use.

The market for antithrombotic medications is expected tbe significantly impacted by COVID-19 infection due tthe quick pace of research. According ta study published in the American Journal of Cardiovascular Drugs in 2020, there are currently more than ten clinical trials evaluating the efficacy of antithrombotic medications in COVID-19 patients. Additionally, research is being done on parenteral administration techniques for these medications for using critically ill COVID-19 patients.

Antithrombotic Drugs Market Report Highlights

Antiplatelet drugs are expected tdominate the market due tincreasing use for clotting as arterial clots comprised primarily of platelets, antiplatelet medications are most effective.

Activities by key players in the market for the development of antiplatelet drugs are expected tdrive the market growth over the forecast period.

Anticoagulant, Thrombolytic, and oral drugs is expected thold the largest market share during the forecast period. Anticoagulants work by interfering with several blood coagulation pathways, making them closely connected tantiplatelet medications and thrombolytic therapies.

Some of the key players operating in the market include Daiichi SankyCompany, Eli Lilly and Company, Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Ko. KG and Aspen Bayer AG, Pfizer, AstraZeneca plc, Johnson & Johnson. AstraZeneca, Otsuka Pharmaceutical, Portola Pharmaceutical Inc., Yuyu Pharma Inc., Limited, Glenmark Pharmaceuticals Limited, China National Pharmaceutical Group Corp, Novartis, Acetlion Pharmaceuticals, Generium Holdings among the others.

Polaris Market Research has segmented the Antithrombotic Drugs market report based on drug type, route of administration, application, end-user and region:

Antithrombotic Drugs market, By Drug Type (Revenue - USD Billion, 2019-2032)

Antiplatelet Drug

Anticoagulant Drug

Thrombolytic Drug

Antithrombotic Drugs market, By Route of Administration (Revenue - USD Billion, 2019-2032)

Oral

Parenteral

Antithrombotic Drugs market, By Application (Revenue - USD Billion, 2019-2032)

Pulmonary Embolism

Deep Vein Thrombosis

Atrial Fibrillation

Others

Antithrombotic Drugs market, By End User (Revenue - USD Billion, 2019-2032)

Hospitals

Ambulatory Surgery Centres

Emergency Service Centres

Others

Antithrombotic Drugs market, Geography (Revenue - USD Billion, 2019-2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa